Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
point decrease » point increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
point decrease » point increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3501
Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
-
3502
Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX
Published 2024“…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
-
3503
Dynamics of PIF4 protein accumulation and autoinhibition in response to temperature.
Published 2025Subjects: -
3504
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3505
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3506
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3507
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3508
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3509
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3510
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3511
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
3512
(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups.
Published 2025Subjects: -
3513
-
3514
Comparison of phenotypes between adult control and <i>aP2-Drp1</i><sup>f/f</sup> mice.
Published 2024Subjects: -
3515
-
3516
-
3517
-
3518
-
3519
-
3520